CO2023000396A2 - Nuevo inhibidor de la secreción de ácido y uso del mismo - Google Patents
Nuevo inhibidor de la secreción de ácido y uso del mismoInfo
- Publication number
- CO2023000396A2 CO2023000396A2 CONC2023/0000396A CO2023000396A CO2023000396A2 CO 2023000396 A2 CO2023000396 A2 CO 2023000396A2 CO 2023000396 A CO2023000396 A CO 2023000396A CO 2023000396 A2 CO2023000396 A2 CO 2023000396A2
- Authority
- CO
- Colombia
- Prior art keywords
- acid secretion
- new inhibitor
- present
- novel compound
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un nuevo compuesto representado por la Fórmula Química 2 o una sal farmacéuticamente aceptable del mismo. El nuevo compuesto de acuerdo con la presente invención presenta un excelente efecto inhibidor de la secreción de ácido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200073900 | 2020-06-17 | ||
PCT/KR2021/007572 WO2021256861A1 (ko) | 2020-06-17 | 2021-06-16 | 신규한 산 분비 억제제 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2023000396A2 true CO2023000396A2 (es) | 2023-02-27 |
Family
ID=79176045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2023/0000396A CO2023000396A2 (es) | 2020-06-17 | 2023-01-13 | Nuevo inhibidor de la secreción de ácido y uso del mismo |
Country Status (16)
Country | Link |
---|---|
US (2) | US11767311B2 (es) |
EP (1) | EP4148050A4 (es) |
JP (1) | JP7404561B2 (es) |
KR (2) | KR102432523B1 (es) |
CN (1) | CN115884968A (es) |
AU (1) | AU2021293694B2 (es) |
BR (1) | BR112022025613A2 (es) |
CA (1) | CA3182882A1 (es) |
CL (1) | CL2022003601A1 (es) |
CO (1) | CO2023000396A2 (es) |
DO (1) | DOP2022000291A (es) |
EC (1) | ECSP23002606A (es) |
MX (1) | MX2022016515A (es) |
PE (1) | PE20231652A1 (es) |
TW (1) | TWI797645B (es) |
WO (1) | WO2021256861A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2021293694B2 (en) | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
WO2023113474A1 (ko) * | 2021-12-15 | 2023-06-22 | 일동제약(주) | 1-설포닐 피롤 유도체의 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
WO2023113458A1 (en) * | 2021-12-15 | 2023-06-22 | Ildong Pharmaceutical Co., Ltd. | Novel salt of 1-sulfonyl pyrrole derivative, preparation method thereof and pharmaceutical composition comprising thereof |
KR20230102353A (ko) * | 2021-12-30 | 2023-07-07 | 주식회사 대웅제약 | 삼중음성유방암의 예방 또는 치료용 약학적 조성물 |
CN114539219A (zh) * | 2022-03-17 | 2022-05-27 | 日照正济药业有限公司 | 一种富马酸伏诺拉生的制备方法 |
WO2023211843A1 (en) * | 2022-04-25 | 2023-11-02 | Daewoong Pharmaceutical Co., Ltd. | Potassium-competitive acid blockers for the treatment of pathological hypersecretory conditions |
WO2023229323A1 (ko) * | 2022-05-23 | 2023-11-30 | 일동제약(주) | 6-메톡시피리딘-3-일 유도체의 제조방법 |
WO2023229322A1 (ko) * | 2022-05-23 | 2023-11-30 | 일동제약(주) | 6-메톡시피리딘-3-일 유도체의 제조방법 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003242390A1 (en) * | 2002-06-14 | 2003-12-31 | Takeda Pharmaceutical Company Limited | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers |
EP2336107B1 (en) * | 2004-09-30 | 2015-09-23 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
PL1919865T3 (pl) * | 2005-08-30 | 2011-09-30 | Takeda Pharmaceuticals Co | 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania |
WO2007114338A1 (ja) * | 2006-03-31 | 2007-10-11 | Takeda Pharmaceutical Company Limited | 酸分泌抑制薬 |
US8933105B2 (en) * | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
AU2009284867B2 (en) * | 2008-08-27 | 2014-08-28 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
NZ595890A (en) * | 2009-03-26 | 2013-09-27 | Takeda Pharmaceutical | Pyrazole compound |
CN110200903B (zh) * | 2012-06-27 | 2022-07-29 | 武田药品工业株式会社 | 用盐稳定的胺和有机酸的液体制剂 |
EP2963019B1 (en) * | 2013-02-28 | 2020-08-12 | Takeda Pharmaceutical Company Limited | Method for producing pyridine-3-sulfonyl chloride |
CN105693693A (zh) * | 2014-11-27 | 2016-06-22 | 江苏柯菲平医药股份有限公司 | 一种吡咯类胃酸分泌和抑制剂化合物盐的制备 |
CN105985278A (zh) * | 2015-01-27 | 2016-10-05 | 江苏柯菲平医药股份有限公司 | 吡咯磺酰类衍生物、其制备方法及其在医药上的应用 |
KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
CN106432191A (zh) * | 2015-08-10 | 2017-02-22 | 陕西合成药业股份有限公司 | 一种新的吡咯类衍生物、其制备方法及其在医药上的应用 |
KR20170113040A (ko) | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
CN109843869B (zh) * | 2016-09-29 | 2021-07-16 | 江苏吉贝尔药业股份有限公司 | 1-[(吡啶-3-基-磺酰基)-1h-吡咯-3-基]甲胺衍生物及其药物组合物和用途 |
BR112020000318A2 (pt) | 2017-07-10 | 2020-07-14 | Takeda Pharmaceutical Company Limited | preparação |
CN110396080B (zh) * | 2018-04-24 | 2022-07-08 | 广东东阳光药业有限公司 | 一种富马酸沃诺拉赞代谢物及其氘代物的制备方法 |
CN108558831B (zh) * | 2018-06-08 | 2021-07-27 | 上海璃道医药科技有限公司 | 取代吡咯-4-烷基胺类化合物及其用途 |
AU2021293694B2 (en) | 2020-06-17 | 2023-12-21 | Ildong Pharmaceutical Co., Ltd. | Novel Acid Secretion Inhibitor and use thereof |
CN111943932B (zh) * | 2020-08-06 | 2023-07-14 | 四川国康药业有限公司 | 一种可以治疗消化性溃疡的3-吡啶磺酰-1-n-杂吡咯衍生物及其制备方法和用途 |
-
2021
- 2021-06-16 AU AU2021293694A patent/AU2021293694B2/en active Active
- 2021-06-16 US US18/011,084 patent/US11767311B2/en active Active
- 2021-06-16 WO PCT/KR2021/007572 patent/WO2021256861A1/ko active Application Filing
- 2021-06-16 JP JP2022577797A patent/JP7404561B2/ja active Active
- 2021-06-16 CN CN202180043522.8A patent/CN115884968A/zh active Pending
- 2021-06-16 KR KR1020210078283A patent/KR102432523B1/ko active IP Right Grant
- 2021-06-16 CA CA3182882A patent/CA3182882A1/en active Pending
- 2021-06-16 PE PE2022002955A patent/PE20231652A1/es unknown
- 2021-06-16 BR BR112022025613A patent/BR112022025613A2/pt unknown
- 2021-06-16 MX MX2022016515A patent/MX2022016515A/es unknown
- 2021-06-16 KR KR1020210078284A patent/KR20210156235A/ko unknown
- 2021-06-16 EP EP21826347.3A patent/EP4148050A4/en active Pending
- 2021-06-17 TW TW110122142A patent/TWI797645B/zh active
-
2022
- 2022-12-15 DO DO2022000291A patent/DOP2022000291A/es unknown
- 2022-12-15 CL CL2022003601A patent/CL2022003601A1/es unknown
-
2023
- 2023-01-13 CO CONC2023/0000396A patent/CO2023000396A2/es unknown
- 2023-01-16 EC ECSENADI20232606A patent/ECSP23002606A/es unknown
- 2023-08-01 US US18/228,672 patent/US20230373954A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4148050A4 (en) | 2023-10-25 |
EP4148050A1 (en) | 2023-03-15 |
WO2021256861A1 (ko) | 2021-12-23 |
DOP2022000291A (es) | 2023-01-15 |
CA3182882A1 (en) | 2021-12-23 |
ECSP23002606A (es) | 2023-03-31 |
JP7404561B2 (ja) | 2023-12-25 |
CN115884968A (zh) | 2023-03-31 |
TW202325702A (zh) | 2023-07-01 |
AU2021293694B2 (en) | 2023-12-21 |
JP2023524172A (ja) | 2023-06-08 |
TW202214588A (zh) | 2022-04-16 |
PE20231652A1 (es) | 2023-10-17 |
KR102432523B1 (ko) | 2022-08-16 |
US20230192650A1 (en) | 2023-06-22 |
KR20210156235A (ko) | 2021-12-24 |
US20230373954A1 (en) | 2023-11-23 |
US11767311B2 (en) | 2023-09-26 |
AU2021293694A1 (en) | 2023-01-19 |
CL2022003601A1 (es) | 2023-07-07 |
TWI797645B (zh) | 2023-04-01 |
BR112022025613A2 (pt) | 2023-01-17 |
KR20210156234A (ko) | 2021-12-24 |
MX2022016515A (es) | 2023-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2023000396A2 (es) | Nuevo inhibidor de la secreción de ácido y uso del mismo | |
AR111495A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
ECSP21000990A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) | |
EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
AR115949A1 (es) | Compuestos heterocíclicos | |
AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
MY196186A (en) | Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor | |
CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
AR119672A1 (es) | Inhibidor de 15-pgdh | |
PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
MX2023006194A (es) | Inhibidor de molecula peque?a de catepsina c y uso medicinal del mismo. | |
CO2021001849A2 (es) | Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende | |
ZA202301937B (en) | Compounds | |
MX2023007476A (es) | Derivado de tetrahidroquinolina y uso medico del mismo. | |
CO2022010431A2 (es) | Nuevo derivado de pirazol | |
CO2019013254A2 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
AR116428A1 (es) | Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo | |
EA202190452A1 (ru) | Ингибиторы cdk8/19 | |
AR083780A1 (es) | Composicion farmaceutica para tratar infecciones del hcv | |
MX2019003907A (es) | Combinaciones farmaceuticas de inhibidor de histona desacetilasa e inhibidor de proteasoma o farmaco inmunomodulador para el tratamiento de cancer hematologico. | |
AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica |